RTP Mobile Logo

Armand P et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36(14):1428-39. Abstract

Barrington SF et al. PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127(12):1531-8. Abstract

Borchmann P et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018;390(10114):2790-802. Abstract

Brentuximab vedotin associated with chemotherapy in untreated patients with stage I/II unfavourable Hodgkin lymphoma. A randomized phase II LYSA-FIL-EORTC Intergroup study. NCT02292979

Bröckelmann PJ et al. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 2018;131(15):1666-78. Abstract

Carella AM et al. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Ann Hematol 2018;97(8):1301-15. Abstract

Connors JM et al; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378(4):331-44. Abstract

Connors JM et al. Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A + AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma: The phase 3 Echelon-1 study. Proc ASH 2017;Abstract 6.

Fornecker L-M et al. PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: First analysis of the primary endpoint of Breach, a randomized phase 2 trial of Lysa-FIL-EORTC Intergroup. Proc ASH 2017;Abstract 736.

Gallamini A et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018;36(5):454-62. Abstract

Goodman A et al. Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade. Proc ASCO-SITC 2018;Abstract 47.

Herrera AF et al. Results from a phase I/II study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Proc ASH 2017;Abstract 649.

Kumar A et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 2016;128(11):1458-64. Abstract

Lynch RC, Advani RH. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book 2016;35:e376-85. Abstract

Moskowitz AJ et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 2017;130(20):2196-203. Abstract

Moskowitz CH et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-62. Abstract

Nademanee A et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant 2018;[Epub ahead of print]. Abstract

Nagle S et al. Brentuximab-induced peripheral neuropathy: Risk factors and patient experiences. Proc ASCO 2017;Abstract 120.

O'Connor OA et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: An international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018;19(2):257-66. Abstract

Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Clin Adv Hematol Oncol 2016;14(2 Suppl 1):17-8. Abstract

Wang CM et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: An open-label phase I trial. Clin Cancer Res 2017;23(5):1156-66. Abstract